Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveal Neoplasms | 2 | 2020 | 310 | 0.260 |
Why?
|
| Melanoma | 4 | 2023 | 5511 | 0.200 |
Why?
|
| Nevus | 1 | 2021 | 204 | 0.170 |
Why?
|
| Environmental Policy | 1 | 2017 | 33 | 0.150 |
Why?
|
| Central Nervous System Cysts | 1 | 2016 | 58 | 0.140 |
Why?
|
| Telomere-Binding Proteins | 1 | 2016 | 116 | 0.130 |
Why?
|
| HIV Envelope Protein gp120 | 4 | 2006 | 952 | 0.130 |
Why?
|
| Muscle Spasticity | 1 | 2016 | 154 | 0.130 |
Why?
|
| Fruit | 1 | 2020 | 1142 | 0.120 |
Why?
|
| Vegetables | 1 | 2020 | 1182 | 0.120 |
Why?
|
| Ataxia | 1 | 2016 | 304 | 0.120 |
Why?
|
| Leukoencephalopathies | 1 | 2016 | 238 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2006 | 1837 | 0.110 |
Why?
|
| HIV-1 | 7 | 2009 | 6939 | 0.100 |
Why?
|
| Thalidomide | 1 | 2016 | 890 | 0.100 |
Why?
|
| Telomere | 1 | 2016 | 910 | 0.090 |
Why?
|
| Retinal Diseases | 1 | 2016 | 684 | 0.090 |
Why?
|
| Measles Vaccine | 1 | 2009 | 76 | 0.080 |
Why?
|
| Tetanus Toxoid | 1 | 2009 | 193 | 0.080 |
Why?
|
| Health Care Reform | 1 | 2017 | 1261 | 0.080 |
Why?
|
| Calcinosis | 1 | 2016 | 1499 | 0.070 |
Why?
|
| Virus Replication | 4 | 2006 | 2535 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 13693 | 0.060 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2007 | 615 | 0.060 |
Why?
|
| Seizures | 1 | 2016 | 2859 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2009 | 1872 | 0.060 |
Why?
|
| CD4 Immunoadhesins | 1 | 2002 | 12 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2017 | 4369 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 5692 | 0.050 |
Why?
|
| Receptors, HIV | 1 | 2002 | 163 | 0.050 |
Why?
|
| New York | 1 | 2023 | 886 | 0.050 |
Why?
|
| Southwestern United States | 1 | 2020 | 37 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2023 | 673 | 0.040 |
Why?
|
| HIV Long-Term Survivors | 1 | 2000 | 126 | 0.040 |
Why?
|
| Gene Products, env | 1 | 2000 | 263 | 0.040 |
Why?
|
| HLA-B Antigens | 1 | 2000 | 354 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2007 | 2232 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 12073 | 0.040 |
Why?
|
| Prescriptions | 1 | 2020 | 387 | 0.040 |
Why?
|
| Health Promotion | 2 | 2020 | 2205 | 0.040 |
Why?
|
| Caspases | 1 | 2000 | 928 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2006 | 4386 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2020 | 764 | 0.030 |
Why?
|
| Kenya | 2 | 2009 | 685 | 0.030 |
Why?
|
| AIDS Vaccines | 1 | 2002 | 938 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 11031 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 8861 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 944 | 0.030 |
Why?
|
| Food Supply | 1 | 2020 | 524 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2000 | 971 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2000 | 1602 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 7914 | 0.030 |
Why?
|
| Receptors, CCR5 | 2 | 2006 | 498 | 0.030 |
Why?
|
| Mutation | 1 | 2016 | 29786 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2020 | 2488 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 8642 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2000 | 2455 | 0.020 |
Why?
|
| Membrane Fusion | 2 | 2002 | 276 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2000 | 4479 | 0.020 |
Why?
|
| Receptors, CXCR4 | 2 | 2006 | 727 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2725 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2020 | 2267 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2020 | 3743 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2021 | 2657 | 0.020 |
Why?
|
| Apoptosis | 2 | 2002 | 9724 | 0.020 |
Why?
|
| Computational Biology | 1 | 2020 | 3519 | 0.020 |
Why?
|
| Humans | 16 | 2023 | 744366 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 2213 | 0.020 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2017 | 1209 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 5856 | 0.020 |
Why?
|
| HIV Infections | 3 | 2009 | 16715 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 2009 | 340 | 0.020 |
Why?
|
| Mammography | 1 | 1997 | 2475 | 0.020 |
Why?
|
| RNA, Viral | 2 | 2007 | 2901 | 0.020 |
Why?
|
| Health Policy | 1 | 2017 | 2661 | 0.020 |
Why?
|
| Zebrafish | 1 | 2016 | 2996 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2009 | 1470 | 0.010 |
Why?
|
| World Health Organization | 1 | 2007 | 1318 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 2002 | 668 | 0.010 |
Why?
|
| Biopolymers | 1 | 2002 | 189 | 0.010 |
Why?
|
| Signal Transduction | 3 | 2014 | 23404 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2007 | 2560 | 0.010 |
Why?
|
| Caspase 6 | 1 | 2000 | 15 | 0.010 |
Why?
|
| NFATC Transcription Factors | 1 | 2002 | 381 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 2000 | 256 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2002 | 758 | 0.010 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2000 | 120 | 0.010 |
Why?
|
| CHO Cells | 1 | 2002 | 1409 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2000 | 182 | 0.010 |
Why?
|
| Cohort Studies | 3 | 2009 | 40559 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 2716 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2014 | 3309 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 2475 | 0.010 |
Why?
|
| Viral Load | 1 | 2007 | 3300 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 1341 | 0.010 |
Why?
|
| Chemokines | 1 | 2002 | 970 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2000 | 906 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2006 | 2967 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2000 | 758 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 18034 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 4561 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2000 | 589 | 0.010 |
Why?
|
| Body Weight | 1 | 2007 | 4671 | 0.010 |
Why?
|
| Female | 5 | 2017 | 380193 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2009 | 41005 | 0.010 |
Why?
|
| Male | 4 | 2017 | 350115 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2000 | 1880 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2002 | 1640 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 4569 | 0.010 |
Why?
|
| Transcription Factors | 2 | 2006 | 12207 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 2002 | 10183 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2000 | 3702 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 4255 | 0.010 |
Why?
|
| Geriatrics | 1 | 1997 | 397 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 6621 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2000 | 1988 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2000 | 3207 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 5524 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 10483 | 0.010 |
Why?
|
| Child | 2 | 2009 | 77709 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 9445 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2007 | 53290 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2000 | 4026 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 5974 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 7798 | 0.010 |
Why?
|
| Animals | 2 | 2016 | 168768 | 0.010 |
Why?
|
| Alleles | 1 | 2000 | 6933 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2000 | 8436 | 0.010 |
Why?
|
| Peptides | 1 | 2000 | 4410 | 0.000 |
Why?
|
| Macrophages | 1 | 2002 | 5660 | 0.000 |
Why?
|
| Cytokines | 1 | 2002 | 7323 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 2002 | 19233 | 0.000 |
Why?
|
| Infant | 1 | 2007 | 35134 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 9647 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 9274 | 0.000 |
Why?
|
| Logistic Models | 1 | 1997 | 13409 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2007 | 63107 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 1997 | 57776 | 0.000 |
Why?
|
| Aged | 1 | 1997 | 163288 | 0.000 |
Why?
|
Concepts
(139)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(6)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_